JP2008541768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008541768A5 JP2008541768A5 JP2008514924A JP2008514924A JP2008541768A5 JP 2008541768 A5 JP2008541768 A5 JP 2008541768A5 JP 2008514924 A JP2008514924 A JP 2008514924A JP 2008514924 A JP2008514924 A JP 2008514924A JP 2008541768 A5 JP2008541768 A5 JP 2008541768A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant retrovirus
- antibody
- cell
- fusion molecule
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 25
- 241001430294 unidentified retrovirus Species 0.000 claims 17
- 230000009870 specific binding Effects 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 102000003886 Glycoproteins Human genes 0.000 claims 3
- 108090000288 Glycoproteins Proteins 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 241000713666 Lentivirus Species 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 241000178568 Aura virus Species 0.000 claims 1
- 241000724653 Borna disease virus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
- 101710154606 Hemagglutinin Proteins 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 206010023927 Lassa fever Diseases 0.000 claims 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 1
- 101710176177 Protein A56 Proteins 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 241000710942 Ross River virus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 239000000185 hemagglutinin Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68621505P | 2005-06-01 | 2005-06-01 | |
| US60/686,215 | 2005-06-01 | ||
| US73807805P | 2005-11-19 | 2005-11-19 | |
| US60/738,078 | 2005-11-19 | ||
| PCT/US2006/021558 WO2006130855A2 (en) | 2005-06-01 | 2006-06-01 | Method of targeted gene delivery using viral vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008541768A JP2008541768A (ja) | 2008-11-27 |
| JP2008541768A5 true JP2008541768A5 (enExample) | 2013-05-23 |
| JP5553989B2 JP5553989B2 (ja) | 2014-07-23 |
Family
ID=37482360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008514924A Expired - Fee Related JP5553989B2 (ja) | 2005-06-01 | 2006-06-01 | ウィルスベクターを使用した標的化遺伝子送達方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20070020238A1 (enExample) |
| EP (2) | EP1885186B1 (enExample) |
| JP (1) | JP5553989B2 (enExample) |
| AU (1) | AU2006252406B2 (enExample) |
| CA (1) | CA2611056C (enExample) |
| WO (1) | WO2006130855A2 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| AU2007275010B2 (en) | 2006-07-21 | 2013-06-20 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| WO2008042814A2 (en) * | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| BRPI0813194B8 (pt) * | 2007-08-03 | 2021-05-25 | Centre Nat Rech Scient | kit, partículas de vetor lentiviral, composição de vetores plasmídicos, antígeno derivado de hiv-1 quimérico, proteína de envelope de vsv-g, moléculas de ácido nucleico, composição imunogênica e uso de um vetor lentiviral |
| CA2787099A1 (en) | 2009-03-30 | 2010-10-14 | Anice C. Lowen | Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof |
| AU2010254136B2 (en) | 2009-05-26 | 2016-09-29 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| US20110015256A1 (en) * | 2009-07-16 | 2011-01-20 | Ihab Mamdouh Ishak Sadek | Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions |
| HRP20140327T4 (hr) | 2009-07-24 | 2017-11-03 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis |
| US9701723B2 (en) | 2010-02-18 | 2017-07-11 | Icahn School Of Medicine At Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| KR20140068205A (ko) | 2011-09-20 | 2014-06-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
| US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| JP2015512263A (ja) | 2012-03-30 | 2015-04-27 | イミューン デザイン コーポレイション | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
| KR20150104117A (ko) | 2012-12-18 | 2015-09-14 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 인플루엔자 바이러스 백신 및 그의 용도 |
| WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| GB201308772D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations Ltd | Vectors |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| US20170051306A1 (en) * | 2014-01-14 | 2017-02-23 | Kagoshima University | Novel method for labelling cancerization-causing cell in stem cells, and therapy method |
| PT3178929T (pt) * | 2014-08-06 | 2021-09-02 | Astellas Pharma Inc | Novo anticorpo anti-ig(beta) humana |
| EP3191136A1 (en) * | 2014-09-08 | 2017-07-19 | Michaela Arndt | Construct for the delivery of a molecule into the cytoplasm of a cell |
| CN108064282A (zh) | 2014-10-14 | 2018-05-22 | 哈洛齐梅公司 | 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法 |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| WO2017004130A1 (en) * | 2015-06-29 | 2017-01-05 | Regents Of The University Of Minnesota | Degradation or neutralization of apobec3b by simian immunodeficiency virus vif |
| WO2017083356A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| BR112018016986A2 (pt) | 2016-02-23 | 2019-02-05 | Immune Design Corp | preparações de vetor retroviral multigenômico e métodos e sistemas para preparação e uso das mesmas |
| PT3377637T (pt) * | 2016-04-08 | 2020-06-17 | Krystal Biotech Inc | Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| US11078282B2 (en) | 2016-04-15 | 2021-08-03 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2017218624A1 (en) | 2016-06-15 | 2017-12-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3529361B1 (en) | 2016-10-20 | 2021-03-24 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| JP2020507349A (ja) | 2017-02-09 | 2020-03-12 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| KR102692556B1 (ko) | 2017-03-16 | 2024-08-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l1 변이체 면역조절 단백질 및 그의 용도 |
| CN110662758A (zh) | 2017-03-16 | 2020-01-07 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
| WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| PT3697810T (pt) | 2017-10-18 | 2026-02-19 | Alpine Immune Sciences Inc | Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados |
| BR112020013236A2 (pt) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso |
| WO2019200163A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| AU2019260757B2 (en) | 2018-04-27 | 2023-09-28 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| AU2019282239B2 (en) | 2018-06-04 | 2024-06-06 | Calidi Biotherapeutics (Nevada), Inc. | Cell-based vehicles for potentiation of viral therapy |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| AU2019346549B2 (en) | 2018-09-24 | 2024-09-12 | Krystal Biotech, Inc. | Compositions and methods for the treatment of Netherton Syndrome |
| EP3876951A1 (en) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| EP3887394A2 (en) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| BR112021014400A2 (pt) | 2019-02-08 | 2021-09-21 | Krystal Biotech, Inc. | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, e, métodos para intensificar, aumentar, elevar e/ou suplementar os níveis de um polipeptídeo cftr em uma ou mais células, para reduzir ou inibir a destruição progressiva do pulmão, para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de fibrose cística e para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de copd |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| SG11202108459QA (en) | 2019-02-27 | 2021-09-29 | Actym Therapeutics Inc | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| CA3140115A1 (en) | 2019-05-23 | 2020-11-26 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
| IL305411A (en) | 2021-02-26 | 2023-10-01 | Kelonia Therapeutics Inc | Lymphocyte-targeted lentiviral vectors |
| CA3213789A1 (en) | 2021-04-02 | 2022-10-06 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
| WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| CN117802163A (zh) * | 2022-09-30 | 2024-04-02 | 深圳市济因生物科技有限公司 | 靶向载体及其制备方法与用途 |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US20250101122A1 (en) | 2023-09-25 | 2025-03-27 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5298420A (en) * | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| AU689755B2 (en) * | 1992-09-22 | 1998-04-09 | Biofocus Discovery Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US20040258688A1 (en) | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| CA2224907A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| FR2747046B1 (fr) | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
| US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
| US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| WO1999013905A1 (en) * | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| ZA988446B (en) | 1997-09-18 | 2000-03-22 | Res Dev Foundation | Production of vaccines using arthropod vectored viruses. |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US7078483B2 (en) * | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| AU3893000A (en) * | 1999-03-16 | 2000-10-04 | Dana-Farber Cancer Institute, Inc. | Lentiviral vector system for high quantity screening |
| WO2000061772A2 (en) | 1999-04-14 | 2000-10-19 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| WO2001016342A1 (en) * | 1999-08-27 | 2001-03-08 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US6534064B1 (en) | 1999-10-13 | 2003-03-18 | Chiron Corporation | Stabilized protein particles for inducing cellular immune responses |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| EP1201750A1 (en) * | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| JP4368196B2 (ja) * | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
| JP2004532012A (ja) | 2001-03-02 | 2004-10-21 | メルク エンド カムパニー インコーポレーテッド | ウイルスリポーター粒子 |
| EP1417236A4 (en) * | 2001-07-10 | 2010-03-17 | Corixa Corp | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES |
| EP1424895B1 (en) | 2001-09-13 | 2009-08-12 | California Institute Of Technology | Method for expression of small antiviral rna molecules within a cell |
| EP1451316B1 (en) | 2001-09-13 | 2014-08-06 | California Institute Of Technology | Method for producing transgenic birds |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| US7195916B2 (en) | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| US6863884B2 (en) * | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| EP1535627B1 (en) | 2002-08-16 | 2008-07-09 | Japan Science and Technology Agency | Recombinant bcg vaccine |
| US20040234504A1 (en) * | 2002-12-18 | 2004-11-25 | Verma Inder M. | Methods of inhibiting gene expression by RNA interference |
| US7090837B2 (en) * | 2003-01-21 | 2006-08-15 | The Salk Institute For Biological Studies | Compositions and methods for tissue specific targeting of lentivirus vectors |
| US7786288B2 (en) | 2003-10-23 | 2010-08-31 | Karp Nelson M | Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site |
| WO2005113584A1 (en) | 2004-04-29 | 2005-12-01 | Board Of Regents, University Of Texas System | Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting |
| US20080227736A1 (en) | 2004-06-03 | 2008-09-18 | Regents Of The University Of California, | Targeting Pseudotyped Retroviral Vectors |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2006031996A2 (en) | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
| US7606802B2 (en) * | 2004-12-22 | 2009-10-20 | Sap Ag | Preserving log files in a distributed computing environment |
| EP1885186B1 (en) * | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| AU2007275010B2 (en) | 2006-07-21 | 2013-06-20 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| EP2222861B1 (en) | 2007-12-11 | 2017-12-06 | The University of North Carolina At Chapel Hill | Polypurine tract modified retroviral vectors |
-
2006
- 2006-06-01 EP EP06772026.8A patent/EP1885186B1/en active Active
- 2006-06-01 WO PCT/US2006/021558 patent/WO2006130855A2/en not_active Ceased
- 2006-06-01 AU AU2006252406A patent/AU2006252406B2/en not_active Ceased
- 2006-06-01 US US11/446,353 patent/US20070020238A1/en not_active Abandoned
- 2006-06-01 JP JP2008514924A patent/JP5553989B2/ja not_active Expired - Fee Related
- 2006-06-01 CA CA2611056A patent/CA2611056C/en active Active
- 2006-06-01 EP EP15177471.8A patent/EP2963118B1/en active Active
-
2011
- 2011-03-04 US US13/041,115 patent/US8821856B2/en active Active
-
2014
- 2014-07-23 US US14/338,947 patent/US9994867B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008541768A5 (enExample) | ||
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| ES2629860T3 (es) | Vectores virales recombinantes | |
| JP7291398B2 (ja) | キメラ分子およびその使用 | |
| Kuate et al. | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies | |
| Pinto et al. | Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers | |
| ES2753854T3 (es) | Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de los mismos | |
| JP6535133B2 (ja) | 新規のバキュロウイルスベクター及び使用の方法 | |
| Szécsi et al. | Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses | |
| RU2013103335A (ru) | Конструкции гомодимерных белков | |
| WO2021213421A1 (zh) | 融合蛋白分子及其制备方法和用途 | |
| ES2775278T3 (es) | Composición formada por un antígeno ligado a un ligando de la superfamilia TNF | |
| JP2013532971A5 (enExample) | ||
| CN111630060A (zh) | 用于在疾病的预防和/或治疗中使用的疫苗 | |
| AU752004B2 (en) | Recombinant Rhabdovirus containing a heterologous fusion protein | |
| CA2831294A1 (en) | Compositions and methods to immunize against hepatitis c virus | |
| Uhlig et al. | Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response | |
| Akhras et al. | Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response | |
| Lu | Combination DNA plus protein HIV vaccines | |
| Neukirch et al. | The potential of adenoviral vaccine vectors with altered antigen presentation capabilities | |
| Bower et al. | DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1 | |
| Wong et al. | An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses | |
| Devitt et al. | Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine | |
| Urban et al. | Retroviral display in gene therapy, protein engineering, and vaccine development | |
| JP7519418B2 (ja) | Ｃｄ４０およびｓｔｉｎｇ経路を活性化する遺伝子アジュバントの発現のためのウイルスベクター構築物 |